Monthly Archives: January 2020

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Urges 500.com (WBAI) Investors to Contact Its Attorneys Immediately, Securities Class Action Filed Against WBAI

SAN FRANCISCO, CA / ACCESSWIRE / January, 29 2020 / Hagens Berman encourages 500.com Limited (NYSE:WBAI) investors who have suffered significant losses to submit their losses now to learn if they qualify to recover their investment losses. A securities class action was recently filed against the company and senior executives, and certain investors may have valuable claims.

Class Period: Apr. 27, 2018 – Dec. 31, 2019

Lead Plaintiff Deadline: Mar. 16, 2020

Sign Up: www.hbsslaw.com/investor-fraud/WBAI

Contact An Attorney Now: WBAI@hbsslaw.com

844-916-0895

500.com Limited (WBAI) Securities Class Action:

The complaint alleges that Chinese online gambling operator 500.com concealed that its executives were bribing Japanese lawmakers to influence Japanese gaming policy and secure the development of a casino resort project in Japan.

The market began to learn the truth on Dec. 27, 2019, when media outlets reported that a Japanese elected official was arrested by Tokyo prosecutors and charged with receiving 3 million yen ($27,400) in cash from 500.com.

Then, on Dec. 31, 2019, 500.com announced the initiation of an internal investigation into alleged illegal money transfers, the concurrent resignation of its Chairman of the Board, and the "temporary" departure of its Chief Executive Officer pending the outcome of the internal investigation.

News of 500.com illegal money transfers caused the price of WBAI ADRs to decline sharply.

"We're focused on investors' losses and proving 500.com concealed its involvement in an illicit lobby scheme," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you purchased shares of 500.com and suffered significant losses, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding 500.com should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email WBAI@hbsslaw.com.

# # #

About Hagens Berman
Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

CONTACT: 
Reed Kathrein
 844-916-0895

SOURCE: Hagens Berman Sobol Shapiro LLP

ReleaseID: 574589

FANDOM SPORTS Media Corp. Announces Share Consolidation

VANCOUVER, BC / ACCESSWIRE / January 29, 2020 / FANDOM SPORTS Media Corp. (CSE:FDM) (OTCQB:FDMSF) (FRANKFURT:TQ42) ("FANDOM SPORTS" or the "Company"), announces that the Company's board of directors has approved and the Company will be completing a share consolidation on the basis of one (1) post-consolidation common share for every ten (10) pre-consolidation common shares (the "Consolidation").

In relation to the share consolidation, the Company has reserved new CUSIP and ISIN which are: 30710L200 and CA30710L2003, respectively. There is no name change or stock symbol change in connection with the Consolidation.

February 7, 2020 was fixed as the record date for the Consolidation. The Consolidation is subject to the approval by the Canadian Securities Exchange. The details of trading with respect to the Consolidation will be announced by a separate news release.

Currently there are 161,677,336 common shares issued and outstanding and after the Consolidation there will be approximately 16,167,734 common shares issued and outstanding. The Company will not be issuing fractional post-Consolidation common shares to shareholders in connection with the Consolidation. Each fractional share remaining after conversion that is less than 1/2 of a share will be cancelled and each fractional share that is at least 1/2 of a share will be changed to one whole share.

A letter of transmittal with respect to the Consolidation will be mailed to registered shareholders of the Company. All registered shareholders with physical certificates will be required to send their respective certificates representing pre-consolidated common shares along with a completed letter of transmittal to the Company's transfer agent, Computershare Trust Company of Canada ("Computershare"), in accordance with the instructions provided in the letter of transmittal. Additional copies of the letter of transmittal will be available on SEDAR.com under the profile of the Company. All shareholders who submit a duly completed letter of transmittal along with their respective pre-consolidated common share certificate(s) to Computershare, will receive a post-consolidation share certificate.

Shareholders who hold their common shares through a broker or other intermediary and do not have common shares registered in their name, will not need to complete a letter of transmittal.

The exercise or conversion price and the number of common shares issuable under any of the Company's outstanding warrants and stock options will be proportionately adjusted to reflect the consolidation in accordance with their respective terms thereof.

About FANDOM SPORTS:

"PLAY. PREDICT. GET REWARDED."

FANDOM SPORTS Media is an entertainment company that aggregates, curates and produces unique fan-focused content.

The FANDOM SPORTS App is the Company's core product, which is the ultimate destination for unfiltered raw sports talk. The app allows passionate sports fans to unleash their primal sports passions, pick fights and earn rewards.

For additional Information:

Investor Relations
Email: info@fandomsports.net

DISCLAIMER:

The CSE has not reviewed and does not accept responsibility for the adequacy and accuracy of this information. This news release may contain forward-looking statements. These forward-looking statements do not guarantee future events or performance and should not be relied upon. Actual outcomes may differ materially due to any number of factors and uncertainties, many of which are beyond the Company's control. Some of these risks and uncertainties may be described in the Company's corporate filings (posted at www.sedar.com).

The Company has no intention or obligation to update or revise any forward-looking statements due to new information or events. This press release contains forward-looking statements about FANDOM SPORTS. Forward-looking statements may be identified by the use of words like "believe," "expect," "anticipate," "estimate," "plan," "consider," "project," and similar references to the future. Forward-looking statements reflect FANDOM SPORTS' good-faith evaluation of information available at the time the forward-looking statements were made. These forward-looking statements are subject to a number of risks and uncertainties, and our actual results may differ materially from those projected. Please refer to FANDOM SPORTS' annual and quarterly reports filed on SEDAR for a full discussion of those risks and uncertainties we view as most important. Forward-looking statements are not, and should not be relied upon as, a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at or by which any such performance or results will be achieved. As a result, actual outcomes and results may differ materially from those expressed in forward-looking statements. We undertake no obligation to update or revise forward-looking statements.

SOURCE: FANDOM SPORTS 

ReleaseID: 574571

Pharma-Bio Serv Announces Results for the Year Ended October 31, 2019

DORADO, PUERTO RICO / ACCESSWIRE / January 29, 2020 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced revenues from continuing operations for the year ended October 31, 2019 were $19.5 million, an increase of $1.7 million, or 9.6%, when compared to last year.

Net income from continued operations for the year ended October 31, 2019 was approximately $2.1 million, an improvement of $3.3 million when compared to last year. This improvement includes last year's non-recurring 2018 US Tax Reform $2.7 million Transition Tax charge recorded in February 2018.

In September 2018, we sold the assets of our laboratory segment. After considering last fiscal year's $2.5 million net income from discontinued operations and related gain on segment disposal and last year's non-recurring 2018 US Tax Reform Transition Tax, our net income for the year ended October 31, 2019 of approximately $2.1 million had an improvement in earnings of approximately $0.8 million over last year's earnings.

"We are satisfied with the results we obtained by focusing our operations on our consulting portfolio of services. We will continue pursuing opportunities for growth which will enhance our Company's value. Finally, we were delighted to provide a dividend of approximately $1.7 million to our loyal shareholders in November 2019," said Victor Sanchez, CEO of Pharma-Bio Serv, Inc.

About Pharma-Bio Serv, Inc.

Pharma-Bio Serv is a compliance, project management, and technology transfer support consulting firm, headquartered in Puerto Rico, with operations in the U.S., Ireland, and Spain. Pharma-Bio Serv's core business is FDA and other international regulatory compliance agency related services. The Company's global team includes leading engineering and life science professionals, quality assurance managers and directors.

Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Pharma-Bio Serv. Forward-looking statements are based on the expectations, estimates, or projections of management as of the date of this news release. Although Pharma-Bio Serv's management believes these expectations, estimates, or projections to be reasonable as of the date of this news release, forward-looking statements are inherently subject to significant business risks, economic and competitive uncertainties, or other contingencies, which could cause its actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Pharma-Bio Serv's actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" section of Pharma-Bio Serv's Annual Report on Form 10-K for the year ended October 31, 2019, and in its other filings with the Securities and Exchange Commission, which filings are available on www.sec.gov. Pharma-Bio Serv disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.

Company Contact:

Pedro J. Lasanta
Chief Financial Officer
787 278 2709

SOURCE: Pharma-Bio Serv, Inc.

ReleaseID: 574591

The Side of The Super Bowl No One Talks About (Maximizing the Super Bowl Platform For The Greater Good of Humanity)

MIAMI, FL / ACCESSWIRE / January 29, 2020 / We are days away and eagerly awaiting Super Bowl LIV where the Kansas City Chiefs will battle the San Francisco 49ers to conclude the 100th season of the National Football League (NFL). This season we have witnessed incredible achievements by the leagues brightest stars. Lamar Jackson comes to mind with an outstanding sophomore season breaking Michal Vicks single season quarterback rushing record, Drew Brees becoming the all-time passing leader and Dereck Henry literally carrying the Tennessee into the playoffs.

It is easy to admire these gifted athletes as they entertain us and exhibit such precision on the field. However, if we peel back the layers and look deep inside who they are we come to find the great women in their lives that have helped these men achieve success. The mothers and wives of these athletes not only take pride being allies of their NFL sons and husbands, they also contribute to society by fighting for the rights of those abused, neglected and less fortunate.

The PFPMA (Professional Football Players Mothers Association) in partnership with the NFL, NFLPA, ProKel Mobility and multiple corporate sponsors will be hosting Galas, Events, and Fundraisers throughout Super Bowl weekend in Miami with the purpose to raise the awareness of human trafficking and aid/support for nonprofits/foundations which help women in distress. This year the organization chose to work with the Heal Her Network, Women In Distress of Broward County Inc, and Off The Field (NFL Wives Association).

Thursday's 1.30.20, PFPMA Kicks Off the Super Mom Experience Luncheon hosted by NFL and NBA sports broadcaster Pam Oliver. This is a women's empowerment luncheon/ silent auction with proceeds going to support Women in Distress of Broward County, Inc. designed to encourage, support, motivate and inspire women and community leaders.

Friday 1.31.20, Off The Field Wives will host their marquee 19th Annual Fashion Show led by Erika Lassiter, Dionne Boldwin, and Kijafa Vick. Wives & significant others of NFL players will walk the runway in fashions from The Miami Design District's retail stores. This show's proceeds will benefit Reach Higher, former First Lady Michelle Obama's initiative to inspire students in the U.S. to complete their education past high school.

Friday 1.31.20 PFPMA, will host an Empowerment Gala that will help support the Miami-Dade's Woman's Fund. R&B Jazz singer, Miles Jaye will be performing live at this network event that will score raise funds from branded sports memorabilia and donations.

Saturday 2.1.20, NFL mom and former domestic violence survivor, Annie Apple, will be hosting victims and survivors of domestic violence, sexual assault, mothers whose children have committed suicide and/or have lost children to gun violence at her Hear Her Super Bowl Huddle event. At an undisclosed location, the participants will enjoy great cuisine, dancing, and an empowering presentation of vulnerability, courage, and sisterhood via her Heal Her Network organization.

National event Coordination Director Sandy Atkins, (Mother of 8-time Pro Bowler and Cincinnati Bengals Defensive Tackle Geno Atkins and Florida resident), states that she's glad that everyone was able to come together from all parts of the country to help those in need here in her hometown.

ProKel Mobility Director of Diversity, Equity & Inclusion, Shantel Drayton, (a South Florida resent as well) states, "I am so happy that ProKel Mobility was able to step in and sponsor the transit initiatives for all the events."

Media Contact:

Shantel Drayton
Director of Diversity, Equity, & Inclusion
(sdrayton@prokelmobility.com)
561.506.5721

SOURCE: Prokel Mobility 

ReleaseID: 574584

Mawson Enters Central Victorian Goldfields in Australia Through Strategic Investment, Direct Project Acquistion and Joint Ventures

VANCOUVER, BC / ACCESSWIRE / January 29, 2020 / Mawson Resources Limited ("Mawson" or the "Company") (TSX:MAW)(Frankfurt:MXR)(OTCPINK:MWSNF) is pleased to announce its entry into the Tier 1 goldfields of central Victoria, Australia, via a multifaceted agreement with major landholder Nagambie Resources Limited (NAG:ASX) ("Nagambie"). Mawson's technical team are consistently reviewing opportunities with a view to generate value for Mawson shareholders through project acquisition, exploration and divestment. The Company believes its Finnish assets and newly acquired Australian assets are a natural fit, bringing together a high-quality gold exploration portfolio in two safe and mining friendly jurisdictions.

"Today's acquisition of gold assets in Victoria, Australia, represents an exciting new opportunity for Mawson. It provides for the outright purchase and joint venture of three high-grade, Fosterville-style (shallow-orogenic or epizonal) exploration projects with numerous historic mines, that lack drill testing to depth, together with a right of first refusal on one of the largest land packages (2000 square kilometres) of high priority exploration ground in the State," commented Mr. Michael Hudson, Chairman and CEO. "Victoria is one of the world's largest orogenic gold provinces, with more than 80 million ounces of gold mined since the 1850s. Following the recent high-grade discovery success at Kirkland Lake Gold's Fosterville mine, the significant potential of shallow orogenic deposits is now better understood."

Webcast Conference Call

The Company will host a webcast conference call to review the acquisition on Thursday, January 30, 2020
at 8:00am ET. Those wishing to join the call can do so using the telephone numbers listed below. The call
will also be webcast and available on the Company's website at www.mawsonresources.com.

Date: Thursday, January 30, 2020 at 8:00am Eastern Time

Participant numbers

Toll Free: 844-602-0380
International: +1 862-298-0970

Replay Number

Toll Free: 877-481-4010
International: +1 919-882-2331
Replay Passcode: 58280

Event Link

https://www.webcaster4.com/Webcast/Page/2197/32999

Transaction Highlights:

Acquisition of three Fosterville-style high-grade gold assets in Victoria, Australia:

A. Clonbinane (100% Acquisition)

Mawson will acquire 100% of the shares of Clonbinane Goldfield Pty Ltd ("CGPL"), a 100% subsidiary of Nagambie and the holder of the Clonbinane mineral tenements ("Clonbinane"), for consideration of A$500,000 cash and 1.0 million Mawson Shares. Mawson will also pay Nagambie A$28,000 to replace environmental bonds.
Clonbinane is a shallow orogenic (or epizonal) Fosterville-style project. Gold mineralization is hosted within, or proximal to diorite dykes with mineralization continuing along structures that extend into the sedimentary country rock.
Mining commenced in 1880s with total production being reported as 41,000 oz gold at a grade of 33g/t gold.
Two small reverse circulation ("RC") and diamond drill campaigns in 1993 and 2008 tested the system between 40 to 100 metres vertical depth over an 800 metre strike (Figures 2-5). Select historic drill results at 0.5g/t gold lower cut included 17 metres at 7.0g/t gold and 0.8% antimony from 66 metres (VCRC022), 38 metres at 2.8g/t gold from 15 metres (VCRC011), 27 metres at 3.7g/t gold and 0.46% antimony from 3 metres (CRC013), 2 metres at 42.5g/t gold and 1.0% antimony from 70 metres (VCRC022). These historical data have not been verified by Mawson and are quoted for information purposes only.
The dyke and historic mine trend continues for 11 kilometres and remains undrilled. 

B. Redcastle (Option and Joint Venture)

Mawson will have the right to earn an up to 70% joint venture interest in Nagambie's Redcastle exploration licence ("Redcastle") by incurring A$1,000,000 in expenditures on Redcastle over a 5 year period.
Redcastle is a shallow orogenic (or epizonal) Fosterville-style historic high-grade project located 7 kilometres along strike from Mandalay Resource's Costerfield mine and on a parallel structure, 24 kilometres east of Kirkland Lake Gold's Fosterville mine (Figure 1).
There are few reliable production records of the early mining at Redcastle; however, high grades of gold and associated stibnite were recorded from nearly all mines, which were only worked to an average of 55 metres depth within a 5 kilometre by 4 kilometre area. The Redcastle Gold Mining Company is reported to have produced 35,000 ounces of gold from Clarke's Reef at a grade of 33g/t gold.
Previous exploration has exclusively focussed on heap leachable near-surface gold and the project remains untested at depth.

C. Doctor's Gully (Option and Joint Venture)

Mawson will have the right to earn an up to 70% joint venture interest in Nagambie's Doctor's Gully retention licence ("Doctor's Gully") by incurring A$1,000,000 in expenditures on Doctor's Gully over a 5 year period.
Doctor's Gully is a shallow orogenic (or epizonal) Fosterville-style gold mineralized district located 13 kilometres northeast of Redcastle (Figure 1). The Doctor's Gully retention licence covers a smaller area of 4 square kilometres with 21 historic gold showings and mines. Modern mining has focused on extracting oxide gold.
RC drilling in 1988, which has never been followed-up, intersected 7 metres @ 4.1g/t gold from 40 metres (WHP7), 8 metres @ 3.2g/t gold from 40 metres (WHP26) and 1 metre @ 14.6g/t gold from 62 metres (WHP26). These historical data have not been verified by Mawson and are quoted for information purposes only.
Like Redcastle, previous explorers at Doctor's Gully have focussed exclusively on heap leachable near-surface gold and the project remains untested to depth.

Strategic 10% equity investment into Nagambie:

Mawson will subscribe for 50.0 million ordinary shares of Nagambie ("Nagambie Shares"), which will represent a 10.0% shareholding in Nagambie. As consideration, Nagambie will receive 8.5 million common shares of Mawson ("Mawson Shares"), which will represent approximately 4.7% of the total issued Mawson Shares (after including the 1.0 million Mawson Shares from the Clonbinane acquisition).
Secures a right of first refusal for Mawson to take up or match proposals being considered over a competitive 2,000 square kilometre tenement package held by Nagambie (Figure 1). This package includes the Nagambie Gold Mine and provides Mawson with a pipeline of potential new projects.
Provides Mawson with a pre-emptive right on future issuances of Nagambie Shares to avoid dilution.

Mr. Hudson, Chairman and CEO, continues, "This acquisition diversifies and adds further high-quality quality gold exploration assets to the Company in another Tier 1 gold district, while we maintain a significant focus on building resources at the Rajapalot project in Finland where five drill rigs are currently operational. Our success in Finland underpins our overall strategy as a gold exploration company, while management's long operating history in both Finland and Australia allows Mawson to bring a highly capable exploration team to continue value creation through discovery. We look forward to working in partnership with Nagambie as we both work to find Victoria's next major gold deposit."

Transaction Overview

Nagambie and Mawson have signed three binding Letter Agreements with respect to the above-noted transactions (collectively, the "Transaction"). The execution of final definitive agreements is targeted for on or before 10 March 2020.

1.  Mawson to become a Cornerstone Supportive Shareholder in Nagambie

Mawson will subscribe for 50.0 million Nagambie Shares which will represent 10.0% of the total issued Nagambie Shares on closing of the Transaction (the "Closing Date"). The Nagambie Shares will be subject to trading restrictions for a period of two years from the Closing Date.

Provided Mawson continues to hold the original 50.0 million Nagambie Shares, Mawson will have a right of first refusal to take up or match any proposals being considered by Nagambie over its 2,000 square kilometres of tenements in the Waranga Domain. The tenement package provides Mawson with a runway of potential new projects and includes the Nagambie Mine, which was mined by Perseverance Corporation, who subsequently bought and mined the heap leach operation at Fosterville (Figure 1). Nagambie will continue to explore in the Waranga Domain using its crustal scale modelling, induced polarization geophysics and drilling to provide Mawson with exposure to potential new projects within a vast 2,000 square kilometre portfolio.

As consideration for the 50.0 million Nagambie Shares, Nagambie will receive 8.5 million Mawson Shares, which will represent approximately 4.7% of total issued Mawson Shares (after including the 1.0 million Mawson Shares from the Clonbinane acquisition). The Mawson Shares will be subject to trading restrictions and will be released from such trading restrictions in 25% tranches at intervals of 4 months, 10 months, 16 months and 22 months from the Closing Date.

2.  Mawson to Purchase 100% of Nagambie's Clonbinane Tenements

Mawson will acquire 100% of the shares in Clonbinane Goldfield Pty Ltd ("CGPL"), a 100% subsidiary of Nagambie and the holder of 62 square kilometres of mineral tenements at Clonbinane, for consideration to Nagambie of A$500,000 cash and 1.0 million Mawson Shares. Mawson will also pay Nagambie A$28,000 to replace environmental bonds. The 1.0 million Mawson Shares will be subject to trading restrictions from the Closing Date and will be released in tranches of 250,000 Mawson Shares at intervals of 4 months, 10 months, 16 months and 22 months from close.

Clonbinane is a shallow orogenic (or epizonal) Fosterville-style deposit located 56 kilometres north of Melbourne. Small scale mining has been undertaken in the project area since the 1880s with total production being reported as 41,000oz gold at a grade of 33g/t gold. Gold mineralization is hosted within, or proximal to, dykes with mineralization continuing along structures that extend into the sedimentary country rock. The diorite dyke and historic working trend continues for 11 kilometres and remains undrilled (Figure 2).

Two small drill campaigns have tested the Clonbinane mineralized system to 40-100 metres vertical depth over an 800 metre strike. In 1986, Ausminde Pty Ltd and Ausminde Holdings Pty Ltd (collectively "Ausminde") were granted mineral tenure at Clonbinane. Ausminde's completed soil and rock chip sampling and undertook RC drilling in 1993 (29 RC drill holes). Beadell Resources Limited subsequently drilled at Clonbinane in 2008 (30 RC holes with 7 diamond drill tails). Drilling results from both these programs greater than 5g/t gold are shown in Table 1. None of the drill data has been independently verified at this time. Compilation of available data and 3D geologic modeling are in progress. The true thickness of the mineralized intervals is not known at this stage. Selected drill results with a 0.5g/t gold lower cut from these two drill programs at Clonbinane included:

17 metres at 7.0g/t gold and 0.8% antimony from 66 metres (VCRC022),
38 metres at 2.8g/t from 15 metres (VCRC011),
27 metres at 3.7g/t gold and 0.46% antimony from 3 metres (CRC013),
2 metres at 42.5g/t gold and 1.0% antimony from 70 metres (VCRC022),
10 metres at 7.0g/t gold from 42 metres (VCRC011), and
5 metres at 11.2g/t gold and 0.78% antimony from 67 metres (VCRC007).

Clonbinane is open at depth and along strike and is considered a high value exploration project with affinity to the Fosterville Mine (Figures 3-5). Mawson will compile all historic mining and exploration data into a 3D model, and look to apply large scale, deeper seeking geophysical methods to identify large mineral systems below 40-100 metres depth.

3. Option and Joint Ventures

Mawson will have the option to earn an up to 70% joint venture interest in each of Nagambie's Redcastle and Doctor's Gully gold properties located in Victoria, Australia by incurring the following exploration expenditures on the each of the properties: A$100,000 in the first year and an additional A$150,000 in year 2 to earn 25%, an additional A$250,000 in year 3 to earn 50% and an additional A$500,000 by year 5 to earn 70%. Once Mawson earns 70% a joint venture between the parties will be formed. Nagambie may then contribute its 30% share of further exploration expenditures or, if it chooses to not contribute, dilute its interest. Should Nagambie's interest be reduced to less than 5.0%, it will be deemed to have forfeited its interest in the joint venture to Mawson in exchange for a 1.5% net smelter return royalty ("NSR") on gold revenue. Should Nagambie be granted the NSR, Mawson will have the right to acquire the NSR for A$4,000,000 per property.

i. Redcastle Option and Joint Venture

Redcastle is a rural locality in central Victoria 45 kilometres east of Bendigo and 18 kilometres north of Heathcote (Figure 1). Redcastle was discovered in 1859, and named the Balmoral Diggings. ‘Redcastle' a name of Scottish origin, displaced Balmoral sometime later. Underground mining continued until 1902.

Redcastle is a shallow orogenic (or epizonal) Fosterville-style historic high-grade orefield held within a tenure area of 51 square kilometres. It is located 7 kilometres along strike from Mandalay Resources' Costerfield mine and on a parallel north-south structure, 24 kilometres east of Kirkland Lake Gold's Fosterville mine. The northern margin of the claim is surround by a Newmont Corporation exploration licence.

There are few historic reliable production records of the early mining at Redcastle, however very high grades of gold and associated stibnite were recorded from nearly all mines, which were only worked to an average of 55 metres depth within a 5 kilometre by 4 kilometre area. The Redcastle Gold Mining Company is reported to have produced 35,000 ounces of gold from Clarke's Reef at a grade of 33g/t gold.

Today six principal prospects or target areas have been identified at Redcastle: Reservoir, Mullocky, Laura, RFZ, Why Not and Pioneer. An RC drill program in 2007-08 by Nagambie totaled 239 holes for 10,169 metres. The average depth of drilling was 42.6 metres with the deepest hole being 81.0 metres and the shallowest hole being 5 metres deep. Of the 14 prospects drilled, 10 intersected gold greater than 1.0g/t gold in 1 metre sample intervals. Composite intersections with an average weighted grade greater than 2.0 ppm gold, using a 0.5g/t gold cut-off are presented in Table 2. None of the drill data have been independently verified at this time. Compilation of available data and 3D geologic modeling are in progress. The true thickness of the mineralized intervals is not known at this stage. Selected drill results from this drill program at Redcastle included: 10 metres at 2.5g/t gold from 22 metres (RRC26), 2 metres at 10.7g/t gold from 39 metres (RRC41) and 2 metres at 6.3g/t gold from 26 metres (PR16).

Previous workers have exclusively focused on heap leachable near-surface gold at Redcastle and the project remains untested to depth. Mawson will compile all historic mining and exploration data into a 3D model, and look to apply large scale, deeper seeking geophysical methods to identify large mineral systems below 50 metres depth.

ii. Doctors Gully Option and Joint Venture

Doctor's Gully is a shallow orogenic (or epizonal) Fosterville-style historic mining district. The Doctor's Gully retention license covers a smaller area of 4 square kilometres with 21 historic gold showings and mines (Figure 1). In modern times it has been mined for oxide gold. It is located 13 kilometres northeast of Redcastle.

Gold Mines of Kalgoorlie ("GMK", also working as Metals Exploration Ltd) mapped and drilled Doctor's Gully in 1988. A total of 1,734 metres of RC drilling was conducted in 29 holes across the prospect. The results from this drill program have never been followed up. Composite intersections are presented in Table 3. None of the drill data has been independently verified at this time. Compilation of available data and 3D geologic modeling are in progress. The true thickness of the mineralized intervals is not known at this stage. Better drill intersections from this program included 7 metres @ 4.1g/t gold from 40 metres (WHP7) and 8 metres @ 3.2g/t gold from 40 metres (WHP26) and 1 metre @ 14.6g/t gold from 62 metres (WHP26).

Like Redcastle, previous workers have exclusively focused on heap leachable near-surface gold at Doctors Gully and the project remains untested at depth. Mawson will compile all historic mining and exploration data into a 3D model, and look to apply large scale, deeper seeking geophysical methods to explore for a large mineral system below 50 metres depth.

Conditions to Closing

The obligation of Mawson to complete the Transaction is subject to, among other matters, Mawson being satisfied in its sole discretion with the material results of its due diligence investigation on Nagambie and its assets (to be completed on or before February 14, 2020) and receipt of TSX approval to the Transaction.

Qualified Person

Michael Hudson, Chairman and CEO for the Company, is a qualified person as defined by National Instrument 43-101 – Standards of Disclosure or Mineral Projects and has prepared or reviewed the preparation of the scientific and technical information in this press release.

None of the drill data has been independently verified at this time. These historical data have not been verified by Mawson and are quoted for information purposes only. Drilling information from Clonbinane by Ausminde and Beadell Resources, at Redcastle by Nagambie and at Doctor's Gully by GMK had a variety of assays and check assays reported in historical reports. It is believed that the primary analysis for gold was completed by fire assay with an atomic adsorption finish by NATA registered laboratories. Assay techniques for antimony are unknown at this stage.

About Mawson Resources Limited (TSX:MAW, FRANKFURT:MXR, OTCPINK:MWSNF)

Mawson Resources Limited is an exploration and development company. Mawson has distinguished itself as a leading Nordic Arctic exploration company with a focus on the flagship Rajapalot gold project in Finland. The Australian acquisition provides Mawson with a strategic and diversified portfolio of high-quality gold exploration assets in two safe jurisdictions.

About Nagambie Resources Ltd (NAG)

Nagambie Resources Ltd ("Nagambie") explores for Fosterville-style, structural-controlled, high-grade sulphide-gold underground deposits within 2,000 sq km of Waranga Domain tenements. Exploration is carried out using geophysical targeting techniques, diamond drilling and analysis for hydrothermal alteration of the sediments.

The Company is also evaluating:

Underwater storage of sulphidic excavation material in the two legacy gold pits at the Nagambie Mine, capable of storing 5 million tonnes of spoil from major infrastructure projects for Melbourne such as Metro Tunnel, West Gate Tunnel and North East Link.
Recycling of the tailings and overburden dumps to produce aggregates for concrete and gravel products respectively.
Quarrying and screening of sand deposits at the mine to produce various sand and quartz aggregate products is planned.

On behalf of the Board,

"Michael Hudson"
Michael Hudson, Chairman & CEO

Further Information
www.mawsonresources.com
1305 – 1090 West Georgia St., Vancouver, BC, V6E 3V7
Mariana Bermudez (Canada), Corporate Secretary,
+1 (604) 685 9316, info@mawsonresources.com

Forward-Looking Statement

This news release contains forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, "forward-looking statements"). All statements herein, other than statements of historical fact, are forward-looking statements. Although Mawson believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are typically identified by words such as: believe, expect, anticipate, intend, estimate, postulate, and similar expressions, or are those, which, by their nature, refer to future events. Mawson cautions investors that any forward-looking statements are not guarantees of future results or performance, and that actual results may differ materially from those in forward-looking statements as a result of various factors, including, but not limited to, capital and other costs varying significantly from estimates, changes in world metal markets, changes in equity markets, planned drill programs and results varying from expectations, delays in obtaining results, equipment failure, unexpected geological conditions, local community relations, dealings with non-governmental organizations, delays in operations due to permit grants, environmental and safety risks, and other risks and uncertainties disclosed under the heading "Risk Factors" in Mawson's most recent Annual Information Form filed on www.sedar.com. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, Mawson disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise.

Figure 1: Plan of Victorian tenement holders, showing location of shallow orogenic (epizonal) Fosterville-style mineralization. Green outlines highlight the area where Mawson has secured a first right of refusal, the 100% purchase of Clonbinane and the Redcastle and Doctor's Gully option and joint venture areas

Figure 2: Plan of the Clonbinane project. Gold mineralization is located within, or proximal to, the dykes with mineralization continuing along structures that extend into the sedimentary country rock with gradually diminishing grades. The dyke and historic working trend extends for 11 kilometres and remains undrilled.

Figure 3: Drill plan of the Clonbinane drilled area showing the best results from two small drill campaigns in 1994 and 2008 that tested the system to 40-100 metres vertical depth over an 800 metre strike (modified after Beadall 2008).

Figure 4: Cross section A-A' (refer to Figure 3) from Clonbinane. The prospect remains open at depth below drillhole VCRC022 which intersected 17 metres at 7.0g/t gold and 0.8% antimony from 66 metres (modified after Beadall 2008).

Figure 5: Cross section B-B' (refer to Figure 3) from Clonbinane (modified after Beadall 2008).

Table 1: Clonbinane Project: Significant results from drilling (>5g/t gold) (from Ravensgate, 2013)

Table 2: Redcastle Project: Significant results from drilling (from Nagambie Resources, 2017)

Table 3: Doctor's Gully Project: Significant results from drilling (from Nagambie Mining Ltd, 2011)

SOURCE: Mawson Resources Limited

ReleaseID: 574585

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against X Financial and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 29, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of X Financial ("X Financial" or "the Company") (NYSE:XYF) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. X Financial's third quarter of 2018 ended just 11 days after the Company's September 2018 IPO. The Company's results for the quartered showed it was suffering from an increase in delinquency rates, a reduction in loans, and a shrinking number of active lenders on its platform. The Company's CEO admitted on March 19, 2019, that its loan volume had been decreasing since the middle of 2018, before its IPO. The Company's Chairman and CEO disclosed on May 21, 2019, that it would be unlikely to achieve significant growth due to the failure of its preferred loan business. Since X Financial's IPO, it has traded as low as $1.65 per ADS compared to its $9.50 per ADS IPO.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 574582

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Correvio Pharma Corp. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 29, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Correvio Pharma Corp. ("Correvio" or "the Company") (NASDAQ:CORV) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

 

Investors who purchased the Company's securities between October 23, 2018 and December 5, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before February 10, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Correvio's resubmission of a New Drug Application ("NDA") for Brinavess did not address significant health and safety issues observed in the Company's first NDA for the drug. The failure to minimize these problems significantly decreased the chances of the FDA approving Brinavess. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Correvio, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 574581

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allakos Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 29, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allakos Inc. ("Allakos" or "the Company") (NASDAQ:ALLK) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Seligman Investments published a report on December 18, 2019, describing Allakos as "A Suspect Biotech with a Phase 2 Farce, Incredulous Trial Investigators, and Warning Signs of Potential Fraud." The report detailed 22 distinct 22 warning signs and signals, including the company having "buried the results for the two AK001 studies it conducted, but our research indicates a debacle," a "checkered history of conducting small, low-credibility trials, marked by . . . discrepancies, omissions, cherry-picking, and other red flags," and engaging in "fragrant nepotism in key clinical roles." Based on this report, shares of Allakos fell by nearly 10% on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Office: 310-301-3335
Cell: 424-303-1964
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 574579

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Portola Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / January 29, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Portola Pharmaceuticals, Inc. ("Portola" or "the Company") (NASDAQ:PTLA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between November 5, 2019 and January 9, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before March 16, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Portola failed to maintain effective internal controls over financial reporting, including reserves for product returns. The Company was actively shipping longer-dated product with a 36-month shelf life, but did not maintain adequate reserves for returns from its prior shipments of shorter-dated product. This put the Company in the position of likely requiring an accounting "catch up" on return reserves. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Portola, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 574580

ALLK LOSSES ALERT: Bernstein Liebhard Reminds Investors of its Investigation of Allakos Inc.

NEW YORK, NY / ACCESSWIRE / January 29, 2020 / Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Allakos Inc. ("Allakos" or the "Company") (NASDAQ:ALLK) from allegations that Allakos might have issued misleading information to the investing public.

If you purchased Allakos securities, and/or would like to discuss your legal rights and options please visit Allakos Shareholder Investigation or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com.

On December 18, 2019, Seligman Research ("Seligman") published a report characterizing Allakos as "A Suspect Biotech with a Phase 2 Farce, Incredulous Trial Investigators, and Warning Signs of Potential Fraud." In addition to many other issues, the Seligman report alleged the Company of having "buried the results for the two AK001 studies it conducted, but our research indicates a debacle."

On this news, Allakos's stock price fell $13.25 per share, or 10%, to close at $119.28 on December 18, 2019.

If you purchased Allakos securities, and/or would like to discuss your legal rights and options please visit https://www.bernlieb.com/cases/allakosinc-allk-shareholder-class-action-lawsuit-stock-fraud-233/apply/ or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com.

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. © 2019 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Matthew E. Guarnero
Bernstein Liebhard LLP
https://www.bernlieb.com
(877) 779-1414
MGuarnero@bernlieb.com

SOURCE: Bernstein Liebhard LLP

ReleaseID: 574576